



Financial Tear Sheet

CORPORATE PROFILE

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our product pipeline candidates utilize the hydrogel technology to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release dosage forms that can be tailored to produce the desired drug release profile. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing. Ocular Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development targeting glaucoma and ocular hypertension. The Company's earlier stage assets include OTX-TIC, a sustained release travoprost intracameral implant targeting moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal implant for the treatment of retinal diseases. These injectable implants include OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is approved to seal corneal incisions following cataract surgery.

STOCK PERFORMANCE

OCUL (Common Stock)

Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	\$5.89
Change (%)	▼ 0.03 (0.51%)
Volume	64,258
52 Week Low	\$4.83
Market Cap	\$171,145,559
Rolling EPS	-2.12
PE Ratio	0
Shares Outstanding	29,056,971

Data as of 10/16/17 4:00 p.m. ET



RECENT NEWS & EVENTS

September 25, 2017 - 8:00 a.m.
[Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer](#)

September 08, 2017 - 9:01 a.m.
[Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer](#)

September 06, 2017 - 4:05 p.m.
[Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences](#)

Date	Title
10/20/17 through 10/22/17	OSN New York Location New York City, NY
11/09/17	OIS @ AAO Location New Orleans, LA
11/11/17 through 11/14/17	American Academy of Ophthalmology Location New Orleans, LA

SEC FILINGS

Filing Date	Form
10/16/17	8-K
10/13/17	8-K
10/03/17	4
10/03/17	4

CORPORATE GOVERNANCE

Amarpreet Sawhney, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors
Jim Fortune	Chief Operating Officer
Peter Jarrett, Ph.D.	Chief Technical Officer
Jonathan Talamo, M.D.	Chief Medical Officer
Eric Ankerud, J.D.	Executive Vice President, Clinical, Regulatory and Quality
Scott Corning	Vice President, Sales and Marketing
Art Driscoll	Vice President, Product Development

Data provided by Nasdaq. Minimum 15 minutes delayed.